AjayKNookaMD

PubMed

• 16 citations
  Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors.
  Amelia Langston, J M Prichard, Samatha Muppidi, Ajay K. Nooka, M.J. Lechowicz
  Bone Marrow Transplantation. 2014-02-01
• 132 citations
  Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
  Alexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, Nizar J Bahlis, H Miles Prince
  Nature Medicine. 2023-09-01
• 46 citations
  Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
  Noffar Bar, Federica Costa, Rituparna Das, Alyssa Duffy, Mehmet Kemal Samur
  JCI Insight. 2020-06-18

Abstracts/Posters

• Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma...
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all